Expert Interview
A second look: Discussing lorundrostat and the Advance-HTN trial for the treatment of hypertension
Ticker(s): MLYSInstitution: The University of Tennessee College of Medicine
- Assistant Professor at the University of Tennessee College of Medicine, Co-Director of complex coronary intervention & Chairs the Interventional Cardiology Chronic Total Occlusion Affinity Group at Ascension Saint Thomas Hospital.
- Has treated ~30 patients with mitral regurgitation using MitraClip.
- Clinical and research focus on the management of complex coronary disease, including chronic total occlusions, imaging, physiology, peripheral arterial revascularization, cardiogenic shock, and management of pulmonary embolism.
What are your thoughts on aldosterone synthase inhibitors as a treatment option for uncontrolled hypertension, and how do they compare to current options such as spironolactone?
Added By: wilson_adminHow do the half-lives of lorundrostat and baxdrostat impact their efficacy, and what are your thoughts on their potential differentiation in trials like ADVANCE-HTN?
Added By: wilson_adminHow do you manage potassium levels in clinical practice, particularly when using aldosterone inhibitors, and what are the potential challenges with hyperkalemia?
Added By: wilson_adminCan you help us understand the prevalence and target patient population for aldosterone synthase inhibitors, and how do these drugs perform in comparison to spironolactone in terms of efficacy and safety?
Added By: wilson_adminWhat is your level of excitement for lorundrostat on a scale from 1 to 10, and what factors could influence the adoption of this new treatment by payers and in clinical practice?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
